Short bowel syndrome (SBS) is a frequently observed condition in individuals with extensive small bowel resections and congenital and mucosal defects. With significant distal small bowel dysfunction or resections, hormones such as Glucagon-like peptide (GLP) 1 and 2 which are essential for regulating gastrointestinal transit, absorption and adaptation, may be deficient. In this case study, a patient with SBS, type 2 diabetes mellitus and high ileostomy outputs secondary to Crohn’s disease was treated with liraglutide, a GLP-1 analogue. Stoma outputs decreased significantly from 6 litres per day down to 1 litre per day with no side effects. This raises the possibility of GLP-1 analogues such as liraglutide being an alternative and effective treatment option for individuals with SBS.